The Neutrophil-to-Lymphocyte Ratio As a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence Beyond Malignant Melanoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Mar 13

PMID 38473401

Authors

Konstantinos Seretis

Konstantinos Sfaelos

Elena Boptsi

Georgios Gaitanis

Ioannis D Bassukas

Affiliations

Soon will be listed here.

Abstract

With the ongoing progress of basic research along with the introduction of new pharmaceutical options spanning almost all therapeutic areas, the need for biomarkers that will be implemented into the personalized medical approach is higher than ever. Their use can be incorporated into clinical practice and can be applied to the classification of disorders and the evaluation of disease severity but also to the monitoring of the progress of therapeutic/pharmaceutical interventions. This systematic review collects the findings of hematologic biomarkers in various cutaneous malignancies, excluding malignant melanoma, to support their potential use in the prognosis but also in the assessment of therapeutic strategies for the specific category of skin disorders.

Citing Articles

Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations.

Cooper R, Ramaswami D, Thomas J, Nieva J, Hsu R Discov Oncol. 2024; 15(1):689.

PMID: 39570469 PMC: 11582238. DOI: 10.1007/s12672-024-01606-9.

From Tumor Macroenvironment to Tumor Microenvironment: The Prognostic Role of the Immune System in Oral and Lung Squamous Cell Carcinoma.

Battista R, Pini G, Finco A, Corso F, Galli A, Arrigoni G Cancers (Basel). 2024; 16(15).

PMID: 39123486 PMC: 11312115. DOI: 10.3390/cancers16152759.

References

Song M, Graubard B, Rabkin C, Engels E . Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep. 2021; 11(1):464. PMC: 7801737. DOI: 10.1038/s41598-020-79431-7. View

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View

Kudura K, Nussbaumer L, Foerster R, Basler L . Inflammatory Blood Parameters as Biomarkers for Response to Immune Checkpoint Inhibition in Metastatic Melanoma Patients. Biomedicines. 2022; 10(9). PMC: 9496082. DOI: 10.3390/biomedicines10092135. View

Li L, Bai Z, Zhang L, Zhang Y, Lu X, Zhang Y . Meta-Analysis of Hematological Biomarkers as Reliable Indicators of Soft Tissue Sarcoma Prognosis. Front Oncol. 2020; 10:30. PMC: 7002470. DOI: 10.3389/fonc.2020.00030. View

Hague C, Farquharson N, Menasce L, Parry E, Cowan R . Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges. Br J Hosp Med (Lond). 2022; 83(4):1-7. DOI: 10.12968/hmed.2021.0149. View

Templeton A, McNamara M, Seruga B, Vera-Badillo F, Aneja P, Ocana A . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju124. DOI: 10.1093/jnci/dju124. View

Vonderheid E, Martinez A . Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019; 19(4):228-238.e4. DOI: 10.1016/j.clml.2018.12.020. View

Petruzzelli M, Ferrer M, Schuijs M, Kleeman S, Mourikis N, Hall Z . Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia. Cancers (Basel). 2022; 14(4. PMC: 8870098. DOI: 10.3390/cancers14040963. View

Forget P, Khalifa C, Defour J, Latinne D, Van Pel M, De Kock M . What is the normal value of the neutrophil-to-lymphocyte ratio?. BMC Res Notes. 2017; 10(1):12. PMC: 5217256. DOI: 10.1186/s13104-016-2335-5. View

10.

Hu H, Archer C, Yip D, Peters G . Clinical predictors of survival in real world practice in stage IV melanoma. Cancer Rep (Hoboken). 2022; 6(2):e1691. PMC: 9939985. DOI: 10.1002/cnr2.1691. View

11.

Valero C, Zanoni D, McGill M, Ganly I, Morris L, Quer M . Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer. Cancer. 2019; 126(5):994-1003. PMC: 7971350. DOI: 10.1002/cncr.32591. View

12.

Zaggana E, Konstantinou M, Krasagakis G, de Bree E, Kalpakis K, Mavroudis D . Merkel Cell Carcinoma-Update on Diagnosis, Management and Future Perspectives. Cancers (Basel). 2023; 15(1). PMC: 9817518. DOI: 10.3390/cancers15010103. View

13.

Eren R, Nizam N, Dogu M, Mercan S, Turgut Erdemir A, Suyani E . Evaluation of neutrophil-lymphocyte ratio in patients with early-stage mycosis fungoides. Ann Hematol. 2016; 95(11):1853-7. DOI: 10.1007/s00277-016-2779-7. View

14.

Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Ohsawa M . Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma. Onco Targets Ther. 2023; 16:263-273. PMC: 10103711. DOI: 10.2147/OTT.S404926. View

15.

Dulmage B, Geskin L, Guitart J, Akilov O . The biomarker landscape in mycosis fungoides and Sézary syndrome. Exp Dermatol. 2016; 26(8):668-676. PMC: 5489366. DOI: 10.1111/exd.13261. View

16.

Scherrer E, Rau R, Lorenzi M, Shui I, Townson S, Larkin J . Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. Future Oncol. 2021; 17(20):2683-2692. DOI: 10.2217/fon-2021-0154. View

17.

Di Raimondo C, Lombardo P, Tesei C, Esposito F, Meconi F, Secchi R . Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Patients with Mycosis Fungoides. Diagnostics (Basel). 2023; 13(11). PMC: 10252222. DOI: 10.3390/diagnostics13111979. View

18.

Wang J, Zhang F, Jiang F, Hu L, Chen J, Wang Y . Distribution and reference interval establishment of neutral-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in Chinese healthy adults. J Clin Lab Anal. 2021; 35(9):e23935. PMC: 8418511. DOI: 10.1002/jcla.23935. View

19.

Xiong S, Dong L, Cheng L . Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021; 14(1):173. PMC: 8529570. DOI: 10.1186/s13045-021-01187-y. View

20.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View